<DOC>
	<DOCNO>NCT00006095</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness vincristine plus irinotecan treating child solid tumor respond previous therapy .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Children With Solid Tumors That Have Not Responded Previous Therapy</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose dose limit toxicity vincristine administer combination irinotecan child refractory solid tumor . - Determine safe tolerable phase II dose combination regimen patient population . - Determine pharmacokinetics combination regimen patient . - Determine incidence severity toxicity combination regimen patient . - Determine preliminary evidence antitumor activity combination regimen patient population . OUTLINE : This dose-escalation study vincristine . Patients receive vincristine IV day 2 first course ( day 1 subsequent course ) day 8 , 15 , 22 , 29 , irinotecan IV 1 hour day 1-5 22-26 . Courses repeat every 6 week absence disease progression unacceptable toxicity . Patients responsive stable disease receive additional course therapy maximum 1 year . Cohorts 3-6 patient receive escalate dos vincristine maximum tolerate dose ( MTD ) reach . The MTD define dose precede least 2 3 2 6 patient experience dose limit toxicity . Patients follow every 6 month 4 year annually thereafter . PROJECTED ACCRUAL : A total 3-12 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm initial diagnosis malignant solid tumor refractory conventional therapy effective therapy exist Brain tumor allow anticonvulsant Brainstem glioma allow without histologic diagnosis Solid lymphoma allow No bone marrow involvement PATIENT CHARACTERISTICS : Age : 1 21 Performance status : Karnofsky 50100 % 10 year age Lansky 50100 % 10 year age Life expectancy : At least 8 week Hematopoietic : Absolute neutrophil count least 1,000/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 8 g/dL ( transfusion allow ) Hepatic : Bilirubin great 1.5 mg/dL ALT le 5 time normal Albumin least 2 g/dL Renal : Creatinine normal age OR Glomerular filtration rate normal age Other : No uncontrolled infection No significant systemic illness Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 1 week since prior biologic therapy recover At least 1 week since prior growth factor No prior stem cell transplantation Chemotherapy : At least 2 week since prior myelosuppressive chemotherapy ( 4 week nitrosoureas ) recover No 2 prior chemotherapy regimens No concurrent cancer chemotherapy Endocrine therapy : Concurrent dexamethasone allow patient CNS tumor provide dose stable decrease least 2 week prior study Radiotherapy : Recovered prior radiotherapy At least 2 week since prior local palliative radiotherapy ( small port ) No prior substantial bone marrow radiotherapy No prior central axis radiotherapy No concurrent radiotherapy Surgery : Not specify Other : No concurrent anticonvulsants No concurrent anticancer therapy investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
</DOC>